Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Meanwhile, here's what real science is doing for patients with advanced pancreatic cancer. And the share price responds accordingly.
https://finance.yahoo.com/news/nantkwest-reports-positive-interim-data-114418563.html
There were a half dozen of us on here reminding them constantly about this scam, laying out the reasons that the technology and the mythical clinical trial on which it was based were flawed. It's no shame to take a loss on an investment but it is when stubbornness prevents ones from recognizing the realities and exacerbates that loss.
The proof is in the stock price.
Not even the corrupt William Barr can defend this company.
You would think that cutting edge technology would merit attention at the ASCO and ESMO annual meetings. I attended both meetings, and nary a mention of the Kenny Wonder Treatment.
No IND...no clinical trial...but the shareholders get a video. LOL
https://www.businesswire.com/news/home/20190625005505/en/PharmaCyte-Biotech-Releases-New-Interviews-Austrianova’s-GMP?fbclid=IwAR3ecrK0kg6laY0MqgOR3sxkBe_3WBuc_ImARdw9caoS16NGh-lynxtVPEM
As low as the share price for PMCB?
Just returned from my 15th ASCO meeting and for the 15th consecutive year, no mention of Pharmacyte, Nuvilex, Austrianova, cell in a box, etc. The perfect record is intact...still on nobody's radar nor will it ever be. Meanwhile, we're seeing PARP inhibitors (BRCA or BRCA-like germline mutations) and other therapies making progress in pancreatic cancer.
given their history of overcoming obstacles and nothing stopping them
This company has NEVER overcome an obstacle in its history, and everything has stopped it from advancing to the mythical clinical trial.
I'll tell you what looking in the rearview is all about. It's about holding out hope for a decades old technology that nobody wanted. It's about being stuck in the chemotherapy past when oncology has moved to targeted therapy and immunotherapy.
I would pick the regimen that appears to have the most promising activity, especially when the 5-year survival rate is only 9%. We've had experience with immunotherapy for several years, and clinicians are understanding how to manage the side effects.
PARP inhibition is also showing activity in pancreatic tumors that are BRCA-positive. PARP inhibitors are already on the market.
As many of us here have been trying to tell you, immuno-oncology is the way forward in pancreatic cancer.
https://www.fiercebiotech.com/research/aacr-apexigen-bms-steal-show-promising-i-o-combo-pancreatic-cancer?mkt_tok=eyJpIjoiWWpGa09HTTJaVEppWWpWbSIsInQiOiJTMlB1UTg4VjhERk1FV2J6T1wvUTg2WXRBVWRrelpQaWt4S1NWZklFNVRYd3ViUkVDVW9UeEZha0NiWHBSM3VCOEE0SlhzVzlUTm5CdVZVTUxFRExNN25JWEJPRDNiTDczaitmUkxIK0c3bEthUkpXOXNkMDNQZk5obGtUbHlxYk4ifQ%3D%3D&mrkid=625554&utm_medium=nl&utm_source=internal
It's a conspiracy. A global hoax, I tell ya. The Chinese must be in on it. Like climate change!
I believe that bearspread recognizes that PMCB is a scam designed to make money for its officers, with no intent to help "the poor cancer patients." This should be obvious by now, after years of empty promises of a mythical clinical trial and IND.
It was a 52-week low. Until today, that is.
Pump away Kenny, your salary depends on it!
Yesterday was the 2-year anniversary of the announcement of a pre-IND meeting with the FDA.
Can anybody tell me the actual date the IND was filed? I can't seem to find it.
https://www.networknewswire.com/pharmacyte-biotech-inc-pmcb-pre-ind-meeting-fda-makes-atm-funding-possible/
It's early in the process but I posted it to show that real progress is being made elsewhere with the latest technology, not some archaic technology that nobody wants and can't even advance to a phase 1 clinical trial.
Nailed it perfectly in one succinct post.
The chance that CIAB with ifosfamide advances to a clinical trial is about as close to zero as one can get.
Years and years of promises, pump and dumps, and no closer today to a mythical trial than 5 years ago.
The scientific community has ignored this archaic technology for good reason. Real progress is being made into finding an effective treatment for pancreatic cancer and it's not coming from PMCB.
If you haven't sold your shares already, please divest, or wait for the next pump that may temporarily lift the share price by 10%.
I'm sure the ESMO conference will be full of talk about CIAB for pancreatic cancer. I'll be in Munich to hear the exciting news firsthand. HaHaHaHaHa!
As I said, cisplatin is not in the comparator arm. The combination that adds cisplatin has already been shown to be superior (at ASCO) to the gemcitabine/nab-paclitxael combo.
Objective: Trial will be designed to show Cell-in-a-Box® + low-dose ifosfamide can serve as an effective and safe consolidation chemotherapy for patients whose tumors no longer respond to the therapy of Abraxane® + gemcitabine or FOLFIRINOX
You're exactly right. I noticed this presentation at ASCO as well.
It seems that standard gemcitabine/ plus nab-paclitaxel will no longer be standard of care. That means that PMCB's comparator arm in its make believe clinical trial will not be the standard treatment.
Agreed. The dump is in progress. Next pumping scam should come in a couple of months.
First comes the pump.
Then comes the dump.
I sold my remaining shares yesterday at 0.10.
Will look to buy back at .05 in anticipation of another pump PR.
It's the only way to make money on this stock.
Indeed. I'll be attending ASCO again next month and, as always, there will be no mention of PMCB or cell in a box. This company exists to enrich management. If you can catch a pump PR and then dump it in time, you can make money. Otherwise you'll be holding the bag.
No point to that story. It does not inform in the least. Head scratcher, and the investment community is treating it as such. Below .05.
That's pretty sad when that's the best part of a supposed major news release. There's absolutely NOTHING in there. Where are the data from the 3-year study that's mentioned? Shouldn't the results of those studies be highlighted? I see NOTHING.
Not the pivotal trial PharmaCyte wanted. And looks like the phase 2b study will have to include metronomic ifosfamide, like bearspread was telling everybody all along. Still doubting that a trial will ever get off the ground. But investors seem to be responding today. Could be a good day to dump.
The never-ending promises but lack of progress over the past several years supports your opinion.
I have returned from ASCO GI in San Francisco, and yet another cancer meeting where cell encapsulation isn't mentioned. There was a lot on pancreatic cancer and findings targets to attack, specifically NTRK or ROS fusions, for which entrectinib works really well (Abstract 521). PARP inhibitors look to have activity in BRCA-positive pancreatic cancer or those that have BRCA-ness.
Naturally, investigators are looking at ways to harness the immune system, and I came across the following when I returned, which will be presented next week at an Immuno-Oncology Symposium, again in San Francisco. I wish I could be there to hear more about. This is an oral agent that can counter the immunosuppressive effects of CCR2-bearing cells.
ChemoCentryx, Inc. , (Nasdaq:CCXI), announced today positive overall survival (OS) results from an ongoing Phase Ib clinical trial of the Company's second CCR2 inhibitor - CCX872 - in the treatment of locally advanced/metastatic pancreatic cancer. The study demonstrated OS of 29% at 18 months with CCX872 and FOLFIRINOX combination therapy in all patients treated. The OS rate of 29% in the present study of CCX872 compares favorably with previously published OS rates of 18.6% using FOLFIRINOX alone to treat pancreatic cancer patients with metastatic disease. The findings will be presented during the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018 in San Francisco, CA.
Just wanted to provide an update in the field for everybody on this board.
A very limited definition.
That's the accepted definition in oncology to indicate a therapy that tries to interrupt activation of a molecular pathway involved in the pathogenesis or exacerbation of a cancer. It's not an attempt by oncologists to devalue anything...oncologists are not out there trying to thwart valuable therapies. To call their carefully selected nomenclature as "noise" is simply not accurate.
bearspread has been using the definition of targeted therapy that has been used by oncologists and pharma for more than a decade. Goes back to ibrutinib (Gleevec) from the early 2000s. There is no molecular pathway being antagonized by CIAB and ifosfamide. No genetic mutation that activates (or inactivates) processes along these pathways is being targeted.
Or perhaps someone is trying to pump the share price by making claims that can't be substantiated.
Agreed. Anybody considering an investment in this scam should read it and avoid the cheerleaders trying to pump it up.
Up from where? It still hasn't touched .044 again.
That spike was short-lived. The half hour it was at .044 was a selling opportunity.
First it was "this will never go below .10." Buying opportunity.
Then it was "this won't go below .08." Buying opportunity.
Followed by "support is at .05." Buying opportunity.
And then "this won't go below .04." Buying opportunity.
.10, .08 and .05 were the selling opportunities!!!
It's not the FDA holding it back.
It's the company itself.
Anybody who is hanging his hat on a rebound by this sham of a company is wasting his resources. There are so many worthy biotechs out there with promising data. Why would somebody invest his money in PMCB and miss out on these other opportunities? I have only been saying this for 2 years.
Why anybody would still have faith in this company escapes me. How many times do you have to be beaten down before you admit the obvious? It was obvious to some of us long ago. Time to throw in the towel...no more hopes....no more dreams. This thing is dead.
Probably sooner than anybody realizes.